📣 VC round data is live. Check it out!
- Public Comps
- Absci
Absci Valuation Multiples
Discover revenue and EBITDA valuation multiples for Absci and similar public comparables like Theravance, Blue Jet Healthcare, Takara Bio, Chabiotech and more.
Absci Overview
About Absci
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Founded
2011
HQ

Employees
157
Website
Financials (LTM)
EV
$734M
Valuation Multiples
Start free trialAbsci Financials
Absci reported last 12-month revenue of $5M and negative EBITDA of ($115M).
In the same LTM period, Absci generated $5M in gross profit, ($115M) in EBITDA losses, and had net loss of ($119M).
Revenue (LTM)
Absci P&L
In the most recent fiscal year, Absci reported revenue of $3M and EBITDA of ($103M).
Absci is unprofitable as of last fiscal year, with EBITDA margin of (3684%) and net margin of (4114%).
Financial data powered by Morningstar, Inc.
Absci Stock Performance
Absci has current market cap of $873M, and enterprise value of $734M.
Market Cap Evolution
Absci's stock price is $5.61.
Absci share price increased by 12.8% in the last 30 days, and by 111.9% in the last year.
Absci has an EPS (earnings per share) of $-0.74.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $734M | $873M | 14.1% | 12.8% | 106.5% | 111.9% | $-0.74 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAbsci Valuation Multiples
Absci trades at 148.7x EV/Revenue multiple, and (6.4x) EV/EBITDA.
EV / Revenue (LTM)
Absci Financial Valuation Multiples
As of May 5, 2026, Absci has market cap of $873M and EV of $734M.
Absci has a P/E ratio of (7.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Absci Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Absci Margins & Growth Rates
In the most recent fiscal year, Absci reported EBITDA margin of (3684%) and net margin of (4114%).
Absci Margins
Absci Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Absci Operational KPIs
Absci's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Absci Competitors
Absci competitors include Theravance, Blue Jet Healthcare, Takara Bio, Chabiotech, MannKind, ARS Pharmaceuticals, Janux Therapeutics, Arbutus Biopharma, Allergy Therapuetics and Alto Neuroscience.
Most Absci public comparables operate across Life Sciences Tools, Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 5.6x | 5.4x | 4.4x | — | |||
| 7.7x | 7.8x | 18.6x | 24.5x | |||
| 2.6x | 2.6x | 17.9x | — | |||
| 1.5x | — | (57.8x) | — | |||
| 3.0x | 2.7x | 20.7x | — | |||
| 8.7x | 6.7x | (4.3x) | — | |||
| (6.5x) | (4.9x) | 0.4x | 0.4x | |||
| 55.0x | 76.3x | (23.5x) | — | |||
This data is available for Pro users. Sign up to see all Absci competitors and their valuation data. Start Free Trial | ||||||
Absci Funding History
Before going public, Absci raised $233M in total equity funding, across 6 rounds.
Absci Funding Rounds
Absci M&A Activity
Absci has acquired 2 companies to date.
Last acquisition by Absci was on June 14th 2021. Absci acquired Totient for $55M (EV/Revenue multiple of ).
Latest Acquisitions by Absci
| Description | Totient is a Cambridge-headquartered biotechnology company using AI and machine learning to discover tissue-specific antigens from tertiary lymphoid structures. The Immunogenomics Platform identifies high-affinity antibodies for oncology, autoimmune disorders, and infectious diseases. Founded in 2017, Totient partners with Takeda and generates candidates from patient tumor samples analyzed in its Boston labs. | Denovium is a Boston-based AI company applying machine learning to drug discovery in biopharma. Its platform accelerates hit identification and lead optimization for protein targets, collaborating with pharmaceutical firms on oncology and immunology programs through generative models trained on proprietary datasets. |
| HQ Country | ||
| HQ City | — | San Diego, CA |
| Deal Date | 14 Jun 2021 | 12 Jan 2021 |
| Valuation | $55M | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Absci acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Absci
| When was Absci founded? | Absci was founded in 2011. |
| Where is Absci headquartered? | Absci is headquartered in United States. |
| How many employees does Absci have? | As of today, Absci has over 157 employees. |
| Who is the CEO of Absci? | Absci's CEO is Sean McClain. |
| Is Absci publicly listed? | Yes, Absci is a public company listed on Nasdaq. |
| What is the stock symbol of Absci? | Absci trades under ABSI ticker. |
| When did Absci go public? | Absci went public in 2021. |
| Who are competitors of Absci? | Absci main competitors include Theravance, Blue Jet Healthcare, Takara Bio, Chabiotech, MannKind, ARS Pharmaceuticals, Janux Therapeutics, Arbutus Biopharma, Allergy Therapuetics, Alto Neuroscience. |
| What is the current market cap of Absci? | Absci's current market cap is $873M. |
| What is the current revenue of Absci? | Absci's last 12 months revenue is $5M. |
| What is the current revenue growth of Absci? | Absci revenue growth (NTM/LTM) is 245%. |
| What is the current EV/Revenue multiple of Absci? | Current revenue multiple of Absci is 148.7x. |
| Is Absci profitable? | No, Absci is not profitable. |
| What is the current EBITDA of Absci? | Absci has negative EBITDA and is not profitable. |
| What is Absci's EBITDA margin? | Absci's last 12 months EBITDA margin is (2339%). |
| What is the current EV/EBITDA multiple of Absci? | Current EBITDA multiple of Absci is (6.4x). |
| What is the current FCF of Absci? | Absci's last 12 months FCF is ($222M). |
| What is Absci's FCF margin? | Absci's last 12 months FCF margin is (4495%). |
| What is the current EV/FCF multiple of Absci? | Current FCF multiple of Absci is (3.3x). |
| How many companies Absci has acquired to date? | As of May 2026, Absci has acquired 2 companies. |
| What was the largest acquisition by Absci? | $55M acquisition of Totient on 14th June 2021 was the largest M&A Absci has done to date. |
| What companies Absci acquired? | Absci acquired Totient and Denovium. |
| In how many companies Absci has invested to date? | Absci hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Absci
Lists including Absci
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
